DK4508045T3 - Citratsalt-former af en muskarinreceptor-agonist - Google Patents

Citratsalt-former af en muskarinreceptor-agonist

Info

Publication number
DK4508045T3
DK4508045T3 DK23757194.8T DK23757194T DK4508045T3 DK 4508045 T3 DK4508045 T3 DK 4508045T3 DK 23757194 T DK23757194 T DK 23757194T DK 4508045 T3 DK4508045 T3 DK 4508045T3
Authority
DK
Denmark
Prior art keywords
receptor agonist
salt forms
muscarinic receptor
citrate salt
citrate
Prior art date
Application number
DK23757194.8T
Other languages
English (en)
Inventor
Giles Albert Brown
Paul Mcgee
Julie Cansfield
Mark Pickworth
Original Assignee
Nxera Pharma Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2211399.7A external-priority patent/GB202211399D0/en
Priority claimed from GBGB2305444.8A external-priority patent/GB202305444D0/en
Priority claimed from GBGB2309615.9A external-priority patent/GB202309615D0/en
Application filed by Nxera Pharma Uk Ltd filed Critical Nxera Pharma Uk Ltd
Application granted granted Critical
Publication of DK4508045T3 publication Critical patent/DK4508045T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK23757194.8T 2022-08-04 2023-08-03 Citratsalt-former af en muskarinreceptor-agonist DK4508045T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2211399.7A GB202211399D0 (en) 2022-08-04 2022-08-04 Muscarinic receptor agonists
GBGB2305444.8A GB202305444D0 (en) 2023-04-13 2023-04-13 Muscarinic receptor agonists
GBGB2309615.9A GB202309615D0 (en) 2023-06-26 2023-06-26 Muscarinic receptor agonists
PCT/EP2023/071591 WO2024028458A2 (en) 2022-08-04 2023-08-03 Muscarinic receptor agonists

Publications (1)

Publication Number Publication Date
DK4508045T3 true DK4508045T3 (da) 2025-10-20

Family

ID=87696205

Family Applications (1)

Application Number Title Priority Date Filing Date
DK23757194.8T DK4508045T3 (da) 2022-08-04 2023-08-03 Citratsalt-former af en muskarinreceptor-agonist

Country Status (29)

Country Link
US (1) US20250340531A1 (da)
EP (2) EP4508045B1 (da)
JP (1) JP2025526601A (da)
KR (1) KR20250041066A (da)
CN (1) CN119866336A (da)
AR (1) AR130114A1 (da)
AU (1) AU2023317835A1 (da)
CA (1) CA3263797A1 (da)
CL (1) CL2025000299A1 (da)
CO (1) CO2025002413A2 (da)
CR (1) CR20250069A (da)
DK (1) DK4508045T3 (da)
DO (1) DOP2025000015A (da)
ES (1) ES3050097T3 (da)
FI (1) FI4508045T3 (da)
HR (1) HRP20251427T1 (da)
IL (1) IL318739A (da)
JO (1) JOP20250025A1 (da)
LT (1) LT4508045T (da)
MA (1) MA69856B1 (da)
MD (1) MD4508045T2 (da)
MX (1) MX2025001312A (da)
PE (1) PE20251236A1 (da)
PL (1) PL4508045T3 (da)
PT (1) PT4508045T (da)
RS (1) RS67422B1 (da)
SI (1) SI4508045T1 (da)
TW (1) TW202416955A (da)
WO (1) WO2024028458A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025030095A1 (en) * 2023-08-03 2025-02-06 Neurocrine Biosciences, Inc. Methods of synthesis
WO2026050229A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Method of treating a neurological or psychiatric disease or disorder
WO2026050231A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Method of treating a bipolar disorder
WO2026050236A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder
WO2026050225A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Method of treating a neurological or psychiatric disease or disorder
WO2026050238A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Muscarinic receptor agonist for use in the treatment of a neurological or psychiatric disorder
WO2026050278A1 (en) 2024-08-27 2026-03-05 Neurocrine Biosciences, Inc. Solid oral pharmaceutical formulations comprising a muscarinic receptor agonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500499TA (en) * 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
SG11201606269WA (en) 2014-02-06 2016-09-29 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists

Also Published As

Publication number Publication date
EP4508045A2 (en) 2025-02-19
MX2025001312A (es) 2025-05-02
AR130114A1 (es) 2024-11-06
CA3263797A1 (en) 2024-02-08
RS67422B1 (sr) 2025-12-31
PE20251236A1 (es) 2025-04-29
EP4663190A3 (en) 2026-03-04
MD4508045T2 (ro) 2026-01-31
CR20250069A (es) 2025-05-26
JP2025526601A (ja) 2025-08-15
AU2023317835A1 (en) 2025-03-20
TW202416955A (zh) 2024-05-01
PT4508045T (pt) 2025-10-29
PL4508045T3 (pl) 2026-03-23
FI4508045T3 (fi) 2025-11-13
CN119866336A (zh) 2025-04-22
DOP2025000015A (es) 2025-04-08
ES3050097T3 (en) 2025-12-19
EP4663190A2 (en) 2025-12-17
JOP20250025A1 (ar) 2025-01-30
WO2024028458A3 (en) 2024-03-21
IL318739A (en) 2025-03-01
MA69856B1 (fr) 2025-10-31
EP4508045B1 (en) 2025-10-01
CO2025002413A2 (es) 2025-06-16
WO2024028458A2 (en) 2024-02-08
US20250340531A1 (en) 2025-11-06
CL2025000299A1 (es) 2025-08-08
LT4508045T (lt) 2025-11-25
SI4508045T1 (sl) 2025-11-28
HRP20251427T1 (hr) 2025-12-19
KR20250041066A (ko) 2025-03-25

Similar Documents

Publication Publication Date Title
DK4508045T3 (da) Citratsalt-former af en muskarinreceptor-agonist
DK4313945T3 (da) Krystallinsk hydrobromidsalt af 5-MeO-DMT
PT3893889T (pt) Composto agonista do recetor e método de preparação e utilização do mesmo
DK4114826T3 (da) Krystallinske former af en farmaceutisk forbindelse
DK3972960T3 (da) Krystallinske former af en btk-hæmmer
EP4199925A4 (en) CYCLOPENTAPYRROLE OREXIN RECEPTOR AGONISTS
DK3335707T3 (da) Kombinationer af en muskarinreceptorantagonist og en beta-2-adrenoreceptor-agonist
SMT201300060B (it) Composti diammidici aventi attivita' di antagonista al recettore muscarinico e di agonista al recettore beta 2 adrenergico
EP3965765A4 (en) OPIOID RECEPTOR ANTAGONIST PRODRUGS
EP3946856A4 (en) OFFSET BASIS FOR ROUTERS
IL304497A (en) Crystalline forms of a pyrrolopyridine-aniline compound
DK1948620T3 (da) Dihydrogenphosphatsalt af en prostaglandin-2D-receptorantagonist
IL281464A (en) Crystal forms of a paranoid X receptor agonist
EP4299572A4 (en) MELANOCORTIN RECEPTOR 4 AGONIST
EP3976587C0 (en) CRYSTALLINE SALT FORMS OF A KINASE INHIBITOR
DK4455141T3 (da) Farmaceutisk acceptabelt salt og krystallinsk form af en glp-1-receptoragonist til behandling af diabetes
IL285510A (en) Substituted amide compounds useful as farnesoid x receptor modulators
DK4097428T3 (da) Vejning af dyr
EP4317153A4 (en) Abhd6 antagonist
EP4304603A4 (en) 5-ht receptor agonist titration
EP4121010A4 (en) Crystalline forms of a farnesoid x receptor agonist
EP3539701C0 (en) MACHINE TOOL CENTER POSITIONING ASSEMBLY STRUCTURE
EP4452969A4 (en) INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS
DK3523310T3 (da) Krystallinske polymorfer af en muscarinacetylcholinreceptoragonist
DK4441028T3 (da) Salt af S-oxprenolol